

Function is more reliable than quantity to follow up the humoral response to the Receptor Binding Domain of SARS- CoV-2 Spike protein after natural infection or COVID-19 vaccination.

Carlos A. Sariol,^{a,b,c†} Petraleigh Pantoja[†], Crisanta Serrano-Collazo^b, Tiffany Rosa-Arocho^b, Albersy Armina^a, Lorna Cruz^{a,b}, E. Taylor Stone^d, Teresa Arana^{a,b}, Consuelo Climent^e, Gerardo Latoni^f, Dianne Atehortua^g, Christina Pabon-Carrero^g, Amelia K. Pinto^d, James D. Brien^d and Ana M. Espino^{a†}

^aDepartment of Microbiology and Medical Zoology, University of Puerto Rico-Medical Sciences Campus, San Juan, PR, USA, ^bUnit of Comparative Medicine, University of Puerto Rico-Medical Sciences Campus, San Juan, PR, USA, ^c Department of Internal medicine, University of Puerto Rico-Medical Sciences Campus, San Juan, PR, USA, ^d Department of Molecular Microbiology and Immunology, Saint Louis University, St Louis, Missouri, USA. ^eBlood Bank Medical Center, Medical Center, San Juan, PR, USA, ^fBanco de Sangre de Servicios Mutuos, Guaynabo, PR, USA, Puerto Rico Science, Technology and Research Trust, PR, USA.

[†]These authors have contributed equally to this work and share first authorship.

*Address correspondence to Carlos A. Sariol carlos.sariol1@upr.edu or Ana M Espino, ana.espino1@upr.edu

Keywords: SARS-CoV-2, COVID-19 Vaccine, Neutralization, Serology, Protection

1 **Abstract**

2 Both the SARS-CoV-2 pandemic and emergence of variants of concern have
3 highlighted the need for functional antibody assays to monitor the humoral response over time.
4 Antibodies directed against the spike (S) protein of SARS-CoV-2 are an important component of
5 the neutralizing antibody response. In this work, we report that in a subset of patients—despite a
6 decline in total S-specific antibodies—neutralizing antibody titers remain at a similar level for an
7 average of 98 days in longitudinal sampling of a cohort of 59 Hispanic/Latino patients exposed to
8 SARS-CoV-2. We also report that serum neutralization capacity correlates with IgG titers, wherein
9 IgG1 was the predominant isotype (62.71%), followed by IgG4 (15.25%), IgG3 (13.56%), and
10 IgG2 (8.47%) at the earliest tested timepoint. IgA titers were detectable in just 28.81% of subjects,
11 and only 62.71% of subjects had detectable IgM in the first sample despite confirmation of
12 infection by a molecular diagnostic assay. Our data suggests that 100% of seroconverting
13 patients make detectable neutralizing antibody responses which can be quantified by a surrogate
14 viral neutralization test. Examination of sera from 10 out of the 59 subjects which had received an
15 initial first dose of mRNA-based vaccination revealed that both IgG titers and neutralizing activity
16 of sera were higher after vaccination compared to a cohort of 21 SARS-CoV-2 naïve subjects.
17 One dose was sufficient for induction of neutralizing antibody, but two doses were necessary to
18 reach 100% surrogate virus neutralization in subjects irrespective of previous SARS-CoV-2
19 natural infection status. Like the pattern seen after natural infection, after the second vaccine
20 dose, the total anti-S antibodies titers declined, however, neutralizing activity remained relatively
21 constant for more than 80 days after the first vaccine dose. The decline in anti-S antibody titer,
22 however, was significantly less in pre-exposed individuals, highlighting the potential for natural
23 infection to prime a more robust immune response to the vaccine. Furthermore, our data indicates
24 that—compared with mRNA vaccination—natural infection induces a more robust humoral
25 immune response in unexposed subjects. However, this difference was significant only when
26 neutralizing antibody titers were compared among the two groups. No differences were observed
27 between naturally infected and vaccinated individuals when total anti-S antibodies and IgG titers
28 were measured. This work is an important contribution to understanding the natural immune
29 response to the novel coronavirus in a population severely impacted by SARS-CoV-2.
30 Furthermore, by comparing the dynamics of the immune response after the natural infection vs.
31 the vaccination, these findings suggest that a functional neutralizing antibody tests are more
32 relevant indicators than the presence or absence of binding antibodies. In this context, our results
33 also support standardizing methods of assessing the humoral response to SARS-CoV-2 when
34 determining vaccine efficacy and describing the immune correlates of protection for SARS-CoV-2.

35 Introduction

36
37 The COVID-19 pandemic presents an unprecedented challenge to the scientific
38 community. At the same time, it is adding advancing our collective knowledge in molecular
39 biology, epidemiology, and immunology at an accelerated speed. One of the crucial questions
40 still under scrutiny is the magnitude and durability of the immune response to natural infection
41 with SARS-CoV-2, especially given the fact that virus-specific antibody (ab) responses are
42 relatively short-lived following SARS-CoV and common cold coronavirus infections (CCC) (Sette
43 and Crotty 2020). Further complicating this scenario is the recent availability of new vaccine
44 formulations, which are accessible to both previously infected and immunologically naïve
45 individuals. The kinetics of the humoral response in vaccinees, both with and without prior
46 SARS-CoV-2 exposure, is an area of active research with many outstanding questions.

47 To begin to address these questions, we followed a cohort of 59 individuals
48 (volunteers or convalescent plasma donors) at different time points following natural infection
49 with SARS-CoV-2. In addition, we chose a set of 7 of those individuals plus 3 additional subjects
50 ($n = 10$) which we then compared with 21 uninfected-vaccinated subjects ($n = 21$). Serum
51 samples for both vaccinated groups were collected between 12 and 28 days after each of the
52 two doses of mRNA vaccine and a third sample was collected between 19 and 83 days after the
53 second dose. Because the limited period of SARS-CoV-2 circulation, studies on the quantity,
54 quality and extent of long-term memory responses are still underway. Recent works on the
55 durability of the humoral immune response after the natural infection with SARS-CoV-2 showed
56 the presence of neutralizing antibodies for several months (Dan et al. 2021, Figueiredo-Campos
57 et al. 2020, L'Huillier et al. 2021, Lau et al. 2021, Wajnberg et al. 2020) or the persistence of IgG
58 responses over the first few months after infection, which is strongly correlated with neutralizing
59 antibody titer (Iyer et al. 2020, L'Huillier, Meyer, Andrey, Arm-Vernez, Baggio, Didierlaurent,
60 Eberhardt, Eckerle, Grasset-Salomon, Huttner, Posfay-Barbe, Royo, Pralong, Vuilleumier, Yerly,
61 Siegrist and Kaiser 2021). Since the onset of the COVID-19 pandemic, functional neutralization
62 assays using serum antibodies has been severely limited due to the requirement for a biosafety
63 level 3 (BSL-3) facility to grow SARS-CoV-2. However, in a relatively short period of time, several
64 surrogate neutralization assays have become available with an excellent performance profile
65 when compared to the classical focus reduction neutralization test (FRNT) (Jeewandara et al.
66 2021, L'Huillier, Meyer, Andrey, Arm-Vernez, Baggio, Didierlaurent, Eberhardt, Eckerle, Grasset-
67 Salomon, Huttner, Posfay-Barbe, Royo, Pralong, Vuilleumier, Yerly, Siegrist and Kaiser 2021,
68 Salazar et al. 2020, Schmidt et al. 2020, Tan et al. 2020, Taylor et al. 2021). For these studies,
69 we choose the cPass SARS-CoV-2 Surrogate Virus Neutralization Test Kit (GenScript, USA)

70 which measures the interaction of purified SARS CoV-2 spike protein receptor binding domain
71 (RBD) with the extracellular domain of the human ACE2 receptor (Taylor, Hurst, Charlton, Bailey,
72 Kanji, McCarthy, Morrison, Huey, Annen, DomBourian and Knight 2021). In our hands, this
73 assay showed the best sensitivity and the lower false negative rate compared to five other
74 assays (Tan, Saw, Chew, Huak, Khoo, Pajarillaga, Wang, Tambyah, Ong, Jureen and Sethi
75 2020). Furthermore, this assay was granted an Emergency Use Authorization (EUA) by the
76 Federal Drug Administration (FDA) for the detection of SARS-CoV-2 neutralizing antibodies.
77 Interestingly, we detected a small number of cases (n = 6) where neutralization activity was still
78 present, although S-specific IgG titers were undetectable by our method (OD <.312).

79 Recently, debate has centered around the efficacy of the natural immune response to
80 SARS-CoV-2 vs. mRNA vaccines. Our work which examines patients in a predominantly Latino
81 population—confirms that following a natural infection neutralizing antibody titers remained
82 detectable at high levels for 4 to 7 months. We also demonstrate that the quantity and the quality
83 of the antibody response induced by the natural infection is significantly higher in titer of both
84 binding and neutralizing antibodies when compared to the response induced by mRNA
85 vaccination. There is limited information regarding the magnitude of the immune response to
86 vaccines against SARS-CoV-2 in naive vs. pre-exposed subjects with clinical trial reports being
87 limited in scope when addressing this issue (Baden et al. 2021, Sahin et al. 2020, Voysey et al.
88 2021, Walsh et al. 2020). Nevertheless, consistent with our findings presented here, a few
89 reports suggest that antibody titers in previously infected persons trend or are significantly higher
90 than in SARS-CoV-2 naïve persons (Bradley et al. 2021, Khoury et al. 2021, Krammer et al.
91 2021, Prendecki et al. 2021). Together the results suggest that a single dose may be sufficient
92 during the early stages of vaccine rollout in order to optimize vaccine availability worldwide.

93

94 **Material and Methods**

95

96 **Cohorts**

97 The samples in this study were derived from two main sources:

98 1-From adult volunteers (> 21 years old) participating in the IRB approved clinical protocol
99 “Molecular Basis and Epidemiology of Viral infections circulating in Puerto Rico”, Pro0004333.
100 Protocol was submitted to, and ethical approval was given by, Advarra IRB on April 21, 2020.
101 This is a running 5 year protocol which encompasses the collection of blood samples from adults
102 exposed or suspected to be exposed to viral infections. An Informed Consent Form and a study
103 questionnaire also approved by the IRB were administered to the volunteers. From March 2020
104 to April 2021, we were able to follow up for serial samples with at least 59 subjects. From those
105 59, five (5) subjects received two doses of Pfizer’s vaccine and two received Moderna’s
106 formulation. We also added three vaccinated subjects for a total of 10 (ID511, ID512 and ID297).
107 From those three, two received Pfizer’s and one Moderna’s vaccine. All three subjects also
108 consented to this study. In addition, a cohort of 21 vaccinated volunteers that were never
109 exposed to SARS-CoV-2 were followed for 6 to eight months (Supplementary tables 1-3). Of
110 these 21 vaccinated volunteers, eighteen (18) received Pfizer’s vaccine and three (3) received
111 Moderna’s formulation. Those 21 subjects are part of the 59 subjects followed for months. During
112 the follow-up period before vaccination, they never had symptoms or a positive serologic result.
113 2- De-identified blood samples received from local laboratories network and blood banks. These
114 subjects were self-enrolled for the purpose of donating plasma for the treatment of COVID-19
115 patients. Subjects were verbally informed regarding the relevance of their participation in COVID-
116 19 research, and were informed of the possibility that their deidentified samples may be used for
117 research purposes. Subjects were given the opportunity to ask questions of blood bank workers
118 regarding their participation. Furthermore, collected samples were handled using the standard
119 blood donors’ protocols, and were accompanied by the blood bank’s signed consent form, which
120 also detailed the possibility that samples would be used for research purposes. In addition, prior
121 to receipt, samples were stripped of all identifiers so that the information cannot be traced back
122 to the individual.

123 As expected, some of the exposed subjects had more symptoms than others, with
124 fever and loss of smell and taste being the most common symptoms. However, in this cohort,
125 subjects did not need hospitalization or additional medical support in an emergency room setting.

126

127 **Detection of SARS-CoV-2 IgM antibodies**

128 CovIgM-Assay is an indirect ELISA for the determination of human IgM antibody
129 class, which was optimized via checkerboard titration. This assay is a Laboratory Developed
130 Test (LDT) with an Emergency Use Authorization (EUA) submitted to the U.S. Federal Drug
131 Administration (FDA) (EUA202043). In summary, microplates were coated overnight at 4°C with
132 2µg/mL of recombinant SARS-CoV-2 S1-RBD protein (GenScript No. Z03483-1) in carbonate-
133 bicarbonate buffer. Plates were washed 3 times with phosphate buffered saline (PBS) containing
134 0.05% Tween-20 (PBST) and blocked for 30 min at 37°C with 250µL/well of 3% Bovine Serum
135 Albumin (BSA) in PBST. Diluted serum or plasma samples (1:100 in blocking buffer) were added
136 in duplicates to the wells and incubated at 37°C for 30 min. The excess antibody was washed off
137 with PBST. Horseradish peroxidase (HRP) labeled-mouse anti-human IgM-mu chain (Abcam)
138 diluted 1:30,000 in PBST was added (100µL/well) and incubated for 30 min at 37°C. After
139 another washing step, TMB solution was added (100µL/well) followed by 15 min incubation. The
140 reaction was stopped by the addition of 50µL/well 10% HCl and the absorbance was measured
141 at 450nm (A450) using a Multiskan FC reader (Thermo Fisher Scientific). In every CovIgM-Assay
142 determination, four wells in which samples were replaced by 100µL/well of PBST were included
143 as background control. Moreover, two in-house controls, a high positive control (HPC) and
144 negative control (NC) were included. HPC and NC were prepared by diluting an IgM anti-SARS-
145 CoV-2 at a concentration of 80µg/mL and 0.070µg/mL, respectively, in PBST containing 10%
146 glycerol. The IgM anti-SARS-CoV-2 was purified from the plasma of a convalescent patient using
147 5/5 HiTrap IgM columns (GE Healthcare, USA). When the OD value of a serum or plasma
148 sample at the working dilution (1:100) was equal or less than the cut-point (OD450= 0.229), the
149 CovIgM-Assay in the sample was assumed to be negative.

150

151 **Detection of SARS-CoV-2 IgG antibodies**

152 IgG antibodies were detected and quantified using the CovIgG-Assay (Espino et al.
153 2020). This assay is a Laboratory Developed Test (LDT) with an Emergency Use Authorization
154 (EUA) submitted to the U.S. Federal Drug Administration (FDA) (EUA201115). It is an indirect
155 ELISA for quantitative determination of human IgG antibody class, which was optimized by
156 checkerboard titration. In summary, disposable high bind flat-bottomed polystyrene 96-wells
157 microtiter plates (Costar, Corning MA No. 3361) were coated overnight at 4°C with 2µg/ml of
158 recombinant SARS-CoV-2 S1-RBD/S2 protein (GenScript No. Z03483-1) in carbonate-
159 bicarbonate buffer (Sigma Aldrich No. 08058). Plates were washed 3 times with (PBST) and
160 blocked for 30 min at 37°C with 250µL/well of 3% non-fat, skim milk in PBST. Samples (serum or
161 plasma) were diluted 1:100 in PBST; 100µL/well was added in duplicates and incubated at 37°C

162 for 30 min. The excess antibody was washed off with PBST. Horseradish peroxidase (HRP)
163 labeled-mouse anti-human IgG-Fc specific (GenScript No. A01854) diluted 1:10,000 in PBST
164 was added (100µl/well) and incubated for 30 min at 37°C. After another washing step, a
165 substrate solution (Sigma Aldrich No. P4809) was added (100µl/well) followed by 15 min
166 incubation. The reaction was stopped with 50µl/well 10% HCl and the absorbance was measured
167 at 492nm (A_{492}) using a Multiskan FC reader (Thermo Fisher Scientific). In every CovIgG-Assay
168 determination two in-house controls, a high positive control (HPC) and negative control (NC)
169 were included. HPC and NC were prepared by diluting an IgG anti-SARS-CoV-2 at a
170 concentration of 30µg/ml and 0.070µg/ml, respectively in PBST containing 10% glycerol. The IgG
171 anti-SARS-CoV-2 was purified from plasma of a convalescent patient using a 5/5 HiTrap
172 rProtein-A column (GE Healthcare, USA). When the OD value of a serum or plasma sample at
173 the working dilution (1:100) was equal or less than the cutoff-point ($OD_{492} = 0.312$), the CovIgG-
174 Assay in the sample was assumed to be negative. However only samples with OD above of
175 0.499 were reported as having a titer within a range of 1:100 to $\geq 1:12,800$.

176 For isotyping ELISAs, the conjugate was changed for the specific isotype as follows: anti-IgA
177 (alpha chain specific-HRP (Sigma), anti-IgG1, 2, 3 and 4 Fc-specific-HRP (Southern Biotech). All
178 conjugates were used in a 1:3,000 dilution.

179

180 **cPass SARS-CoV-2 neutralization antibody detection method**

181 To determine the neutralizing activity of antibodies we used a surrogate viral
182 neutralization test (C-Pass GenScript sVNT, Piscataway NJ) (Tan, Saw, Chew, Huak, Khoo,
183 Pajarillaga, Wang, Tambyah, Ong, Jureen and Sethi 2020, Taylor, Hurst, Charlton, Bailey, Kanji,
184 McCarthy, Morrison, Huey, Annen, DomBourian and Knight 2021). Briefly, serum or plasma
185 samples were diluted according to manufacturer's instructions and incubated with soluble SARS-
186 CoV-2 receptor binding domain (RBD-HRP) antigen for 30 minutes, mimicking a neutralization
187 reaction. Following incubation, samples were added to a 96 well plate coated with human ACE-2
188 protein. RBD-HRP complexed with antibodies are removed in a wash step. The reaction is
189 developed with tetramethylbenzidine (TMB) followed by a stop solution allowing the visualization
190 of bound RBD-HRP to the ACE2. Since this is an inhibition assay, color intensity is inversely
191 proportional to the amount of neutralizing antibodies present in samples. Data is interpreted by
192 calculating the percent of inhibition of RBD-HRP binding. Samples with neutralization activity of
193 $\geq 30\%$ indicates the presence of SARS CoV-2 RBD-interacting antibodies capable of blocking the
194 RBD-ACE2 interaction thus inhibiting viral entry into host cells. While this assay measures the

195 blocking activity of those antibodies, for consistency and clarity this activity is referred to
196 throughout the text as 'percentage of neutralization'.

197

198 **Statistical Methods**

199 Statistical analyses were performed using GraphPad Prism 7.0 software (GraphPad
200 Software, San Diego, CA, USA). The statistical significance between or within groups evaluated
201 at different time points was determined using two-way analysis of variance (ANOVA) (Tukey's,
202 Sidak's or Dunnett's multiple comparisons test) or unpaired t-test to compare the means. The p
203 values are expressed in relational terms with the alpha values. The significance threshold for all
204 analyses was set at 0.05; p values less than 0.01 are expressed as $P < 0.01$, while p values less
205 than 0.001 are expressed as $P < 0.001$. Similarly, values less than 0.005 are expressed as
206 $P < 0.005$. Cohen's Kappa agreement follow Landis and Koch scale. The values (κ) were
207 considered as follows: poor agreement, $\kappa < 0.02$; fair agreement, $\kappa = 0.21$ to 0.4; moderate
208 agreement, $\kappa = 0.41$ to 0.6; substantial agreement, $\kappa = 0.61$ to 0.8; very good agreement, $\kappa = 0.81$ to
209 1.0.

210 **Results**

211 **Sample collection**

212 Subjects were enrolled and samples were collected as participants became willing
213 and available. However, the time between serial samples was very similar for all subjects. The
214 average time between the time of the documented infection and the first samples (n=59) was
215 40.37 days (minimum 12 days, maximum 97 days and two extreme cases with 127 and 176 days
216 for a median of 38 days). Once the subjects entered in the cohort, the average time between the
217 first and the second samples (n=59) was 67.86 days (minimum 7 days, maximum 111 days,
218 median 67.5 days). The average time between the second and the third samples (n=12) was
219 99.5 days (minimum 63 days, maximum 159 days, median 95 days) (Supplementary table S1).
220 From the two subgroups, exposed-vaccinated and unexposed-vaccinated, serum samples were
221 collected between 15 to 20 days after each dose. In addition, a third sample from all 21
222 unexposed and from 8 out of the 10 pre-exposed participants was collected between 19 and 83
223 days after the second dose (average of 40.1 and of 81.6 days for the unexposed and pre-
224 exposed groups respectively) or an average of 60.3 and 100.5 days after the first vaccine dose
225 for the unexposed and pre-exposed groups respectively (Supplementary table S2). Highly
226 relevant for our findings is that the sample used as baseline in the pre-exposed before
227 vaccination, was collected in average 142 days after the confirmed infection (minimum 67 days,
228 maximum 310 days, median 126.4 days) (Supplementary table S3).

230 **SARS-CoV-2 specific IgG titers decline over time**

231 Overall, the IgG titers in the cohort of 59 subjects were significantly higher (geometric
232 mean 1072) in the first set of samples than the second set of samples (geometric mean 618) ($p <$
233 0.0473) or the third set of samples (geometric mean 537) ($p < 0.0474$). We observed no
234 significant differences between titers measured in the second and third sets of samples ($p <$
235 0.3085) (Figure 1A). The results are reported as OD450 in supplementary figure 1A and agree
236 with estimated titers (Supplementary table S4).

237 Of the 59 subjects naturally exposed to the virus, 40 (67.8%) experienced a decrease
238 in IgG titers (Figure 1B) while 19 (32.2%) showed an increase in the IgG titers from the first to
239 the second set of samples (Figure 1C). We found no relationship between the elapsed time from
240 initial diagnosis to first sample collection and the change (e.g. increase or decrease) in IgG titers
241 between sample collections (Supplementary figure 2). From these results, we concluded that the
242 differences in the IgG titers in those groups from the first to the second set of samples were not
243 attributable to the time between collection. We also found no relationship between the elapsed

244 time between the first and second sample collection for both groups (Supplementary figure 2).
245 We identified three subjects (ID137, ID195, and ID367) showing a unique trend towards an
246 increase in IgG titers of 2.13-, 8.65-, and 52.1-fold, respectively, between the second and third
247 sampling collections. Particularly, volunteer ID195 exhibited an initial 8.65-fold decrease in IgG
248 titer between the first and second sample collection (50 days elapsed) followed by an increase in
249 IgG titer between the second and third sample collection (75 days elapsed).

250

251 **SARS-CoV-2 specific IgM titers decline over time**

252 Among the 59 subjects in our cohort, 37 (62.71%) had detectable IgM titers in the
253 first set of samples, while 18 (30.50%) had detectable IgM titers in the second set of samples
254 (Supplementary figure 1H). In five subjects out of the 12 where a third sample was collected, IgM
255 titers were still detectable. In some cases, subjects developed an IgM response for first time (in
256 volunteer ID313 IgM was detected as early as 12 days after the presumptive diagnosis and
257 persisted up to 192 days, or roughly 6.4 months). Overall, IgM titers showed a consistent pattern
258 of decline in the second sample for most individuals (86.44%). Only one subject (ID265) showed
259 no appreciable change in IgM titers between the first and second sample collection (68 days
260 elapsed). One subject (ID313) displayed no measurable IgM titer at the time of the first and
261 second sampling (106 days elapsed), but appeared positive for IgM titers in the third sample
262 (146 days elapsed). We also found that in the second set of samples, 3 subjects out of 59
263 (5.08%) displayed detectable IgM titers which were absent detectable IgG titers. Subject ID312
264 showed detectable IgM titers, but borderline IgG titers results in the third sample collected 57
265 and 69 days after the first and second dose, respectively (86 and 98 days after the presumptive
266 diagnosis). Subject ID105 still had detectable IgM titers 192 days after the presumptive diagnosis
267 was made. The earliest time point with detectable IgM titers was 12 days after the presumptive
268 infection (ID166), followed by 13 days (ID180) and 14 days (ID179) after diagnosis. In general,
269 IgM was detected in 37 subjects (77.97%) in the first set of samples (43 days post presumptive
270 infection). In 18 subjects (57.63%), IgM was detected in the first and second set of samples (104
271 days post presumptive infection). In 4 subjects (6.77%) no IgM was detected in any of the serial
272 samples collected.

273

274 **IgG titers—but not IgM or IgA titers—correlate with neutralizing activity.**

275 As described previously, the correlation between estimated IgG titers by the CovIgG-
276 Assay and the neutralization capacity as measured by the Focus Reduction Neutralization Test
277 (FRNT) is extremely strong (Espino, Pantoja and Sariol 2020). For this work, we performed same

278 analysis examining the correlation between IgG titers and functional neutralization capacity,
279 obtained in these studies using the surrogate assay cPass SARS-CoV-2 neutralization antibody
280 detection method. By applying a Kappa analysis, we first aimed to determine if both techniques
281 agree when classifying positive and negative samples using <100% and >30% as cutoff for the
282 IgG titers and percentage of neutralization respectively. We found moderate agreement between
283 IgG titer and neutralization capacity, with a Cohen's Kappa value of 0.4304 (Supplementary figure
284 3A). We then aimed to determine whether both techniques agree when classifying samples with
285 high IgG titers and high neutralizing antibody titer. Similarly, we found moderate agreement
286 between IgG titer and neutralization capacity, with a Cohen's Kappa value of 0.5402
287 (Supplementary figure 3B). We completed the same analysis for IgM and IgA titers to explore the
288 contribution of those antibody subclasses to total neutralization capacity. We found that both
289 techniques (IgM titer and cPass) have a fair agreement when classifying positive and negative
290 samples (Cohen's Kappa = 0.2391), while the IgA titer and the neutralization assay showed only a
291 slight agreement (Cohen's Kappa = 0.0618) (Supplementary figure 3C-D).

292

293 **Neutralizing activity remains constant over time**

294 To determine the durability of the neutralizing antibody response, we examined the
295 neutralization capacity in our longitudinally collected samples. Our results showed consistent
296 neutralizing antibody titers over time, with no change in the neutralization potential from the first
297 (geometric mean 68.08%) to the second (geometric mean 63.89%) sample. Similarly, we saw no
298 appreciable decline in neutralization potential from the second (geometric mean 63.89%) to the
299 third (geometric mean 60.36%) sample (Figure 1D and supplementary table S4). We did,
300 however, identify two distinct trends in the kinetics of serum neutralization potential over time.
301 Similar to our findings with total IgG titers, in the first collected sample we found a decrease in
302 the neutralizing activity relative to the second sample in 61.01% (36 out of 59) of the subjects.
303 Conversely, 38.98% of subjects (23 out of 59) showed a decrease in neutralization activity
304 (Figures 1E and F) during the same timeframe. While the percentage of subjects experiencing an
305 increase or a decrease in neutralization capacity and IgG titers between samples was similar, the
306 change in neutralization capacity was less pronounced and not significant compared with
307 significant changes in the IgG titers (Figure 1B). From these findings, we concluded that the
308 neutralizing capacity remains relatively constant during the time we followed this cohort.

309 Similarly, we compared the neutralization potential of sera from subjects in the
310 second and the third samples for the few subjects (n = 3) for which we were able to obtain a third
311 sample. We identified one subject (ID313) showing a different pattern, with a 3.34-fold (68%)

312 increase in neutralizing activity from the second to the third sample. Another two subjects
313 showed an increase in IgG titers, but displayed a very limited increase in neutralizing activity of
314 1.2-fold (ID135) and 0-fold (ID195). Despite the variability in IgG titers, neutralizing activity
315 remained over 50% in a majority (90%) of all three samples. The distinctive serological and
316 neutralization pattern for subject ID313 appears to be strongly related to the clinical evolution
317 (Supplementary figure 3).

318 We also identified 11 subjects without detectable SARS-CoV-2 specific IgG titers which showed
319 some degree of neutralization ranging from 36% to 76%. Six out of those 11 subjects had no
320 detectable total IgG. On the other hand, there were 3 subjects with detectable IgG titers capable
321 of binding SARS-CoV-2 S protein, but with very limited or absent neutralization capacity
322 (Supplementary table S4).

323

324 **Natural infection induces high quality antibodies than one vaccine dose.**

325 Next, we wanted to compare the magnitude of the humoral immune response to
326 naturally acquired SARS-CoV-2 infection to the mRNA-based COVID-19 vaccinations in
327 unexposed subjects. For this purpose, we choose samples from 25 participants out of the 59 with
328 the first sample collected between 12 and 39 days after the confirmed infection with SARS-CoV-
329 2 (average 26.23 days) and from 21 unexposed participants that received two doses of the
330 Pfizer-BioNTech vaccine. Samples for the unexposed subjects were collected an average of 17.1
331 and 14.1 days after the first and the second dose, respectively. As shown in Figure 2A, the mean
332 time elapsed between the first sample collection after infection was significantly higher than the
333 time elapsed between the first sample collected after the vaccination in the unexposed cohort
334 ($p < 0.0001$). Despite this delay, we found that the total anti-S antibodies and the total IgG titers
335 were comparable after the infection or the first vaccine dose in the unexposed participants
336 (Figures 2B and D). However, the quality of the antibodies measured by the surrogate
337 neutralization assay showed a neutralizing activity significantly higher in the naturally infected
338 group compared with the unexposed-vaccinated group ($p < 0.0003$). This indicated to us a better
339 quality of the antibodies induced by naturally acquired infection when compared to vaccine-
340 induced neutralizing antibody activity (Figure 2D). As showed in Figures 2B and 2C, two vaccine
341 doses in unexposed individuals were necessary to significantly increase the total antibody titers
342 and IgG titers compared to individuals in the pre-exposed group ($p < 0.0004$). The magnitude of
343 neutralization was also significantly increased in pre-exposed individuals, but more modestly
344 than the quantity ($p < 0.0294$), suggesting that the increase in antibody quantity induced by the

345 two vaccine doses was not accompanied by a similar increase in the quality of the neutralizing
346 antibody response (Figure 2D).

347

348 **Neutralization is sustained in naïve and pre-exposed-vaccinated subjects**

349 Samples were collected between 12 to 28 days after each dose with a mean of 19
350 days and of 14 days for the pre-exposed group and of 12 days and 26 days for the unexposed
351 groups after the first and second dose respectively. An additional third sample from all 21
352 unexposed individuals and from 8 out of the 10 pre-exposed individuals was collected between
353 19 and 83 days after the second dose, respectively (Supplementary table S2). For the first
354 sample collected following the first dose, there were no significant differences in the time elapsed
355 between sample collections for the pre-exposed and unexposed subjects. However, there was a
356 significant difference ($p < 0.0001$) in the time elapsed between sample collections following the
357 second dose (third sample) between the pre-exposed and unexposed groups (Supplementary
358 figure S4). The geometric mean baseline IgG titers in the pre-exposed population was 726
359 (range: 125 to 7191) and increased to a geometric mean of 5239 (range: 3408 to 6586) after the
360 first dose (Figure 3B and supplementary tables S5 and S6). After the second dose, the geometric
361 mean decreased to 3980 (range: 2273 to 5847), and we observed no significant difference in IgG
362 titers after the first dose. On the other hand, the 21 vaccinated, unexposed subjects were
363 negative for S-specific IgG at baseline. After the first dose, the IgG titers significantly increased
364 to a geometric mean of 832 (range: 196 to 9365, $p < 0.0001$) and after the second dose, those
365 values significantly increased ($p < 0.0001$) to a geometric mean of 5446 (range: 3346 to 10,239)
366 (Figure 3B).

367 In the second sample, which was collected after the second dose (third sample) in the
368 unexposed group, the geometric mean of the titers was 1518 (range: 409 to 3278). In the pre-
369 exposed group, the geometric mean of the titers was 1323 (range: 568 to 3536). In both groups,
370 we observed a significant decrease from the IgG titers detected in the first samples relative to
371 titers after the second dose ($p < 0.0001$ and $p = 0.0192$ for the unexposed and pre-exposed
372 groups, respectively).

373 In our cohort, the total IgG values were consistent with reported IgG titers (Figure 3A).
374 We looked first at the IgG1 isotype, the main contributor to the total IgG in the cohort of 59
375 individuals. The first dose induced a significant increase in this isotype for both groups ($p < 0.0018$
376 and $p < 0.0001$ for the unexposed and pre-exposed vaccinated groups, respectively). However,
377 the effect of the boost was significantly higher in the pre-exposed group ($p < 0.0001$) suggesting a
378 role for natural infection in this significant difference. Remarkably, the second dose appeared to

379 provide a benefit in boosting IgG1 titers in the unexposed, vaccinated group only ($p < 0.0001$).
380 IgG1 values after the second dose in the unexposed, vaccinated group reached values
381 comparable to that of the pre-exposed vaccinated group after just one dose. We observed no
382 significant differences in the levels of IgG1 between groups following the second dose
383 (Supplementary Figure 5).

384
385 The geometric mean baseline of neutralization activity in the pre-exposed population
386 was 69.46% (range: 39 to 97%) and increased significantly ($p < 0.0001$) to a geometric mean of
387 97.99% (range: 97 to 98%) after the first dose (Figure 3C and Supplementary Table S5).
388 However, following the second dose, the values remained similar in range, with a mean of
389 97.19%. On the other hand, the 21 naïve-vaccinated persons were negative for neutralization at
390 baseline (geometric mean: 15%). After the first dose, neutralization significantly increased
391 ($p < 0.0001$) to a geometric mean of 57.34% (range: 28% to 76%, with one outlier of 96%). The
392 second dose produced an additional significant boost ($p < 0.0001$) to a geometric mean of 96.85%
393 (in a range from 95% to 98%) (Figure 3C). Contrary to the trend we observed in total antibody
394 titers and IgG titers (Figures 3A and B), the neutralizing activity was retained at very similar level
395 in both groups in the third sample collected. The geometric mean for the unexposed group was
396 94.5% (in a range from 86% to 98%), while the pre-exposed group had a geometric mean of
397 96.62% (in a range from 96% to 98%). Though there was no significant difference in
398 neutralization capacity between groups, nine (9) subjects in the unexposed group showed values
399 lower than 5% neutralization. This resulted in a 1.02-fold decrease in the value of neutralization
400 capacity in the unexposed group, while there were no changes in neutralization capacity the pre-
401 exposed cohort.

402 Among the previously exposed subjects we examined, 5 out of 10 (50%) retained
403 detectable IgM at baseline (i.e. the time of the first sampling). IgM titer did not appear to be
404 boosted by the first vaccine dose, and titers decreased after the second dose. On the other
405 hand, the first dose did appear to induce a significant increase ($p < 0.0001$) in the IgM values in
406 the unexposed subjects. Those values were boosted only in two subjects, but as expected, were
407 not modified in any of the other 19 subjects (Supplementary Figure 5). Eight (8) out of the 21
408 unexposed patients (38.09%) had no detectable IgM after the first dose. Only one patient failed
409 to develop measurable IgM antibodies after the two vaccine doses.

410 Finally, we looked at the contribution of the IgA isotype to the immune response after
411 vaccination. Interestingly, we found that this isotype was significantly boosted in both groups,
412 pre-exposed ($p < 0.0187$) and unexposed groups ($p < 0.0010$) after the first vaccine dose. In

413 addition, the increase in IgA titers was significantly higher in the pre-exposed ($p < 0.0176$)
414 vaccinated group compared to the unexposed, vaccinated group. The second boost resulted in
415 an additional significant increase in IgA titers in the unexposed, vaccinated population but not in
416 the pre-exposed vaccinated group (Supplementary Figure 5).

417 Discussion

418 Our study followed a cohort of 59 subjects with prior exposure to SARS-CoV-2 with
419 the goal of describing the kinetics of the humoral immune response to natural infection over time.
420 This study uniquely examined a population of Hispanic/Latino persons disproportionately
421 impacted by the COVID-19 pandemic. We compared the kinetics of this antibody response in the
422 context of individuals with naturally acquired infection (pre-exposed) and unexposed individuals
423 following vaccination. None of the exposed subjects in our cohorts required hospitalization and
424 only had mild to moderate symptoms. Because of that, we found no differences in the serological
425 response according to symptoms severity. Consistent with other reports, we found that antibody
426 titers tended to wane over time and added to a growing body of evidence suggesting that
427 functional neutralization assays should serve as the gold standard for evaluating vaccine efficacy
428 in lieu of antibody binding quantification. Furthermore, we found that pre-exposed individuals
429 were able to mount an antibody response after just one vaccination dose that was equivalent to a
430 two-vaccine dose regiment in unexposed individuals. These findings have important implications
431 for defining the correlates of protection for SARS-CoV-2, as well as recommendations for future
432 public health guidelines and vaccine distribution efforts on a global scale.

433 One limitation of our work is the limited number of subjects sampled following natural
434 infection or vaccination. However, we were able to draw statistically significant conclusions from
435 our studies using 59 individuals. Additionally, our findings in this limited dataset are consistent
436 with previous reports, which have made great contributions to our understanding of the
437 immunological response to SARS-CoV-2 with a similar number of subjects (Bradley, Grundberg,
438 Selvarangan, LeMaster, Fraley, Banerjee, Belden, Louiselle, Nolte, Biswell, Pastinen, Myers and
439 Schuster 2021, Geers et al. 2021, Krammer, Srivastava, Alshammary, Amoako, Awawda, Beach,
440 Bermúdez-González, Bielak, Carreño, Chernet, Eaker, Ferreri, Floda, Gleason, Hamburger,
441 Jiang, Kleiner, Jurczynszak, Matthews, Mendez, Nabeel, Mulder, Raskin, Russo, Salimbangon,
442 Saksena, Shin, Singh, Sominsky, Stadlbauer, Wajnberg and Simon 2021, Predecki, Clarke,
443 Brown, Cox, Gleeson, Guckian, Randell, Pria, Lightstone, Xu, Barclay, McAdoo, Kelleher and
444 Willicombe 2021).

445 We also acknowledge that setting up a longitudinal cohort study is always a
446 challenge. Particularly for COVID-19, it imposed additional difficulties due to the lockdowns,
447 social distancing measures, stigma associated with positive testing, and other significant
448 barriers. However, we assert that the limitations regarding the sampling sequence do not detract
449 from the significance of our findings.

450 Notably, our results contrast with reports describing a short persistence of neutralizing
451 antibodies in plasma donors (Annen et al. 2021), but are in agreement with recent work
452 indicating that neutralizing antibodies may persist longer (Dan, Mateus, Kato, Hastie, Yu, Faliti,
453 Grifoni, Ramirez, Haupt, Frazier, Nakao, Rayaprolu, Rawlings, Peters, Krammer, Simon,
454 Sapphire, Smith, Weiskopf, Sette and Crotty 2021, Klingler et al. 2020, Wajnberg, Amanat, Firpo,
455 Altman, Bailey, Mansour, McMahon, Meade, Mendu, Muellers, Stadlbauer, Stone, Strohmeier,
456 Aberg, Reich, Krammer and Cordon-Cardo 2020). Another work showed a long-term stabilization
457 of anti-Spike IgG value and nAbs lower than in early days post symptoms onset in a hospitalized
458 cohort (Dispinseri et al. 2021). The effect we are seeing in the samples with a decrease in the
459 total antibodies and titers in the second sample may be also a stabilization at a plateau. We have
460 followed up samples from 8 out of the 10 pre-exposed vaccinated subjects, but unfortunately,
461 alterations in the humoral response due to vaccination of these subjects limit our interpretation of
462 these results. Interestingly, the same group reported that nAbs are a correlate of survival and
463 that nAbs and, that anti-spike IgG persists in the vast majority of recovered patients regardless of
464 disease severity, age, and co-morbidities for up to eight months from symptoms onset
465 (Dispinseri, Secchi, Pirillo, Tolazzi, Borghi, Brigatti, De Angelis, Baratella, Bazzigaluppi, Venturi,
466 Sironi, Canitano, Marzinotto, Tresoldi, Ciceri, Piemonti, Negri, Cara, Lampasona and Scarlatti
467 2021). A longer follow up period would further our understanding of the antibody kinetics in a
468 long-term period

469 We were able to show a similar trend in our cohort, with sustained neutralizing activity
470 during the frame time of this study. The sustained neutralization capacity we observed remains
471 highly relevant, despite the significant decline of IgG titers that we observed in this cohort. In
472 addition, we found that some subjects with undetectable IgG (n=6) and IgG titers (n=11) retain
473 measurable neutralization activity, ranging from 32 to 76 %, as measured by a surrogate virus
474 neutralization assay. This finding is consistent with previous reports, suggesting that SARS-CoV-
475 2 serological assays may be poorly-suited for prediction of serum neutralization potency, a metric
476 necessary to facilitate the establishment of the appropriate serologic correlates of protection
477 against SARS-CoV-2 (Muecksch et al. 2020). Our results suggest that functional assays
478 measuring neutralization potential should be implemented in studies of vaccine efficacy at the
479 population level.

480 From a technical point of view, the discrepancies between samples without detectable
481 antibodies but with neutralizing capabilities may be explained by differences in assays'
482 sensitivity. In our case, we use the same source of recombinant proteins for the antibodies and
483 surrogate neutralization assays. However, the serological assays include the full S1 and S2

484 regions of the Spike protein, which includes the RBD, to coat the plate. The neutralization assay,
485 however includes only the S1/RBD in suspension. It has been well documented that the binding
486 of the protein to the plate results in altered antigen accessibility with a consequent presentation
487 of different antigenic sites compared to native proteins (de Thier et al. 2015, Güven et al. 2014,
488 Mannik et al. 1997, Taylor, Hurst, Charlton, Bailey, Kanji, McCarthy, Morrison, Huey, Annen,
489 DomBourian and Knight 2021). Nevertheless, we showed a 93.7% correlation between IgG titers
490 and neutralization measured with a cPass SARS-CoV-2 Neutralizing Antibody Detection kit.

491 There are a limited number of publications on the contribution of different antibody
492 isotypes to the immune response to this novel coronavirus. Early studies reported that spike- and
493 RBD-specific IgM, IgG1, and IgA antibodies were detected in most subjects early after infection,
494 with all samples displaying neutralizing activity and IgM and IgG1 contributing most to
495 neutralization (Klingler, Weiss, Itri, Liu, Oguntuyo, Stevens, Ikegame, Hung, Enyindah-Asonye,
496 Amanat, Baine, Arinsburg, Bandres, Kojic, Stoever, Jurczynszak, Bermudez-Gonzalez, Nádas,
497 Liu, Lee, Zolla-Pazner and Hioe 2020). A recent work reported that in a hospitalized cohort early
498 presence of anti-RBD anti-spike IgA positively correlated with reduced persistence of SARS-
499 CoV-2 RNA in naso-pharyngeal swabs (Dispinseri, Secchi, Pirillo, Tolazzi, Borghi, Brigatti, De
500 Angelis, Baratella, Bazzigaluppi, Venturi, Sironi, Canitano, Marzinotto, Tresoldi, Ciceri, Piemonti,
501 Negri, Cara, Lampasona and Scarlatti 2021). Other work reported that early SARS-CoV-2-
502 specific humoral responses were dominated by IgA antibodies and that virus-specific antibody
503 responses included IgG, IgM, and IgA. Furthermore, some studies have found that the IgA
504 isotype contributes to virus neutralization to a greater extent compared with IgG (Sterlin et al.
505 2021). In agreement with our results, recent work from India, a heavily impacted country by the
506 pandemic found that RBD-specific IgG but not IgA or IgM titers, correlated with neutralizing
507 antibody titers and RBD-specific memory B cell frequencies (Nayak et al. 2021). In our work, we
508 found that IgG1 was the predominant isotype, while the IgA response was more limited.
509 However, considering the non-significant changes in the IgA levels from the first to the second
510 sample, a role for IgA in sustained neutralization activity cannot be ruled out. On the other hand,
511 in the majority of subjects in this cohort, IgM showed an expected trend to decline in the second
512 collected sample. Two out of four subjects (ID265 and ID382) which were IgG-/IgM+, also had
513 detectable neutralizing activity with detectable IgM both two and four months after the first
514 samples were collected. These cases suggest that in some individuals, IgM may contribute to
515 sustained neutralization capacity, as has been described before (Klingler, Weiss, Itri, Liu,
516 Oguntuyo, Stevens, Ikegame, Hung, Enyindah-Asonye, Amanat, Baine, Arinsburg, Bandres,
517 Kojic, Stoever, Jurczynszak, Bermudez-Gonzalez, Nádas, Liu, Lee, Zolla-Pazner and Hioe 2020).

518 This result also corresponds with a Kappa analysis suggesting a fair Cohen's Kappa agreement
519 between IgM titers and neutralization capacity. Additional isotype-specific depletion experiments
520 are needed to determine the role of these antibodies in SARS-CoV-2 neutralization. Using
521 previous experience from our group (Serrano-Collazo et al. 2020, Steffen et al. 2020) those
522 experiments are underway using a larger number of well characterized individuals.

523 While the number of subjects in our vaccinated cohort (both unexposed and
524 previously exposed subjects) is limited, we show that vaccination induces a higher boost in the
525 magnitude of the humoral immune response, both at the level of S-specific IgG and
526 neutralization ability in the pre-exposed individuals compared to the naïve group. Our findings
527 also indicate that the second vaccine dose did not expand the S-specific antibodies, the total IgG
528 titers, or the neutralization capacity of blocking antibodies beyond the peak reached after the first
529 dose in the case of the pre-exposed cohort. One subject (ID112) received the Moderna
530 formulation (ID112) was identified as unexposed and without any known exposure to the SARS-
531 CoV-2, reach values in all three determinations comparable to that of the pre-exposed subjects.
532 Notably, however that volunteer worked in a high-risk environment during the first months of the
533 pandemic, and asymptomatic infection cannot be ruled out despite the absence of measurable
534 S-specific and neutralizing antibody titers at baseline.

535 Our study revealed two significant findings regarding vaccination. First is the rapid
536 decline of anti-S antibodies just 40 to 80 days (for unexposed or pre-exposed cohorts,
537 respectively) after a boost with the mRNA vaccine formulations. Second is the sustained level of
538 neutralization ability in the same period that anti-S antibodies are declining. This pattern is the
539 same as the one observed following naturally acquired SARS-CoV-2 infection in 59 subjects. In
540 addition, we observed that—while in both groups the decline of the total anti-S antibodies and
541 IgG titers was significant—the decline in titers was more precipitous in the unexposed group
542 relative to the pre-exposed group. Also highly significant is the observation that the baseline
543 neutralizing activity—but not the total antibody titers—was significantly higher among pre-
544 exposed individuals than the neutralization capacity induced by the first vaccine dose in the
545 unexposed group. This finding is reinforced by the fact that the time after natural infection and
546 the sample use as baseline before the vaccination was more than 4.7 months in average for all
547 10 pre-exposed subjects. Our results also confirm that antibodies generated after the natural
548 infection, while similar in quantity, are significantly better in their function when natural infection
549 preceded vaccination. These results suggest that natural infection with SARS-CoV-2 may
550 contribute to the expansion of memory B cells, enabling the production of more S-specific
551 antibodies following vaccination. Together, these findings highlight the value of measuring both

552 the function and quantity of S-specific antibodies to follow up humoral immune responses to the
553 vaccination. Our results agree with recent work wherein a predictive model of immune protection
554 from COVID-19 found that the level of neutralizing antibodies is highly predictive of immune
555 protection from symptomatic SARS-CoV-2 infection (Khoury, Cromer, Reynaldi, Schlub,
556 Wheatley, Juno, Subbarao, Kent, Triccas and Davenport 2021) and associated to recovery
557 (Dispinseri, Secchi, Pirillo, Tolazzi, Borghi, Brigatti, De Angelis, Baratella, Bazzigaluppi, Venturi,
558 Sironi, Canitano, Marzinotto, Tresoldi, Ciceri, Piemonti, Negri, Cara, Lampasona and Scarlatti
559 2021).

560 Our results on neutralization are built on using the RBD sequence from the original
561 SARS-CoV-2 virus. We do not know the variants infecting the subjects. However, all 59 subjects
562 in the serial sample's cohort were exposed to the SARS-CoV-2 from March to December 2020.
563 Only the 3 additional subjects in the pre-exposed and vaccinated cohorts were confirmed as
564 positive in the first two weeks of January 2021. During that period information about the
565 circulating variants in Puerto Rico was very limited. The first variant identified in Puerto Rico was
566 the Alpha variant (first identified in the UK, B.1.1.7) and was reported on January 28th, 2021. In
567 addition, from March 2020 to December 2020 the Government of Puerto Rico imposed a strict
568 lockdown limiting the travels to the island requiring mandatory testing upon arrival. By July 21st,
569 2021, reports from the Surveillance System from the PR Department of Health and other private
570 institutions reported about 950 cases, with patients infected with at least nine (9) different
571 variants as follows: UK Alpha (B.1.1.7), New York (B.1.526), Brazil Gamma (P.1), California
572 Epsilon (B.1.429) and (B.1.427), California Eta (B.1.525), India Delta (B.1.617), Brazil Zeta (P.2),
573 Sudafrica Beta (B.1,351), India Kappa (B.1.617). We acknowledge that the neutralizing
574 properties of our samples may be modified when tested against the RBD from the variant of
575 interest and variant of concerns. However, a work testing four variants representing the original
576 SARS-CoV-2 strain and emerging variants with mutations in the spike protein suggested that
577 infection- and vaccine-induced immunity may be retained against the B.1.1.7 variant (Edara et al.
578 2021).

579 Of interest is the role of previous natural infection in driving antibody isotype
580 switching. Particularly in the case of IgA, our results showed that previous exposure led to a
581 faster increase in IgA titers after the first dose of vaccination, while unexposed subjects required
582 a second dose of vaccine to reach same levels of IgA titer of those pre-exposed to the novel
583 coronavirus.

584 Another critical aspect to be considered is the timing between the natural infection
585 and a potential vaccination against COVID-19. In accordance with the findings of other groups,

586 we highlighted the relevance of the time elapsed between infections or immunizations to induce
587 an optimal immune response (Miller et al. 2008, Pulendran and Ahmed 2006, Serrano-Collazo,
588 Pérez-Guzmán, Pantoja, Hassert, Rodríguez, Giavedoni, Hodara, Parodi, Cruz, Arana, Martínez,
589 White, Brien, de Silva, Pinto and Sariol 2020). Taking into account the results presented here
590 and those from previous works (Bradley, Grundberg, Selvarangan, LeMaster, Fraley, Banerjee,
591 Belden, Louiselle, Nolte, Biswell, Pastinen, Myers and Schuster 2021, Kumar et al. 2020,
592 Predecki, Clarke, Brown, Cox, Gleeson, Guckian, Randell, Pria, Lightstone, Xu, Barclay,
593 McAdoo, Kelleher and Willicombe 2021), and considering the limited vaccine availability
594 worldwide, our findings suggest that immunity conferred by a single dose may be sufficient to
595 provide immune protection from severe disease in previously-exposed individuals. With this in
596 mind, second doses in previously exposed individuals may be deferred until the final phases of
597 vaccination campaigns and/or to be executed not before than 6 months after the documented
598 infection. Because of the limited number of samples, we were unable to identify any significant
599 differences between the Pfizer-BioNTech or Moderna vaccine formulations.

600 We are aware of the limitations of this work owing to the limited number of
601 participants and associated clinical data. We also understand that this work would benefit from
602 an examination of the T cell compartment in unexposed and pre-exposed vaccinees, particularly
603 in light of recent evidence that simple serological tests for SARS-CoV-2 antibodies do not reflect
604 the richness and durability of immune memory to SARS-CoV-2 (Dan, Mateus, Kato, Hastie, Yu,
605 Faliti, Grifoni, Ramirez, Haupt, Frazier, Nakao, Rayaprolu, Rawlings, Peters, Krammer, Simon,
606 Sapphire, Smith, Weiskopf, Sette and Crotty 2021). With this in mind, experiments characterizing
607 the T cell response in our cohorts are underway.

608 Nevertheless, this work provides new and additional insight to the limited available data on
609 COVID-19 immune phenomena. Furthermore, this work also advances our understanding of
610 immune responses to the mRNA vaccine formulations in unexposed and pre-exposed
611 individuals, outside of the data provided by the vaccine manufactures. From our results, as well
612 as others (Bradley, Grundberg, Selvarangan, LeMaster, Fraley, Banerjee, Belden, Louiselle,
613 Nolte, Biswell, Pastinen, Myers and Schuster 2021, Khoury, Cromer, Reynaldi, Schlub,
614 Wheatley, Juno, Subbarao, Kent, Triccas and Davenport 2021, Krammer, Srivastava,
615 Alshammary, Amoako, Awawda, Beach, Bermúdez-González, Bielak, Carreño, Chernet, Eaker,
616 Ferreri, Floda, Gleason, Hamburger, Jiang, Kleiner, Jurczynszak, Matthews, Mendez, Nabeel,
617 Mulder, Raskin, Russo, Salimbangon, Saksena, Shin, Singh, Sominsky, Stadlbauer, Wajnberg
618 and Simon 2021, Predecki, Clarke, Brown, Cox, Gleeson, Guckian, Randell, Pria, Lightstone,
619 Xu, Barclay, McAdoo, Kelleher and Willicombe 2021), the usefulness of a second vaccine dose

620 in pre-exposed subjects remains inconclusive. Furthermore, the immune response elicited by
621 these vaccine formulations needs to be further evaluated to include the T cell compartment,
622 which serves as a critical component in the response to SARS-CoV-2 (Dan, Mateus, Kato,
623 Hastie, Yu, Faliti, Grifoni, Ramirez, Haupt, Frazier, Nakao, Rayaprolu, Rawlings, Peters,
624 Krammer, Simon, Sapphire, Smith, Weiskopf, Sette and Crotty 2021, Grifoni et al. 2020,
625 Predecki, Clarke, Brown, Cox, Gleeson, Guckian, Randell, Pria, Lightstone, Xu, Barclay,
626 McAdoo, Kelleher and Willicombe 2021, Weiskopf et al. 2020). Undoubtedly, natural infection
627 confers a strong and high quality humoral and cellular immune response (Dan, Mateus, Kato,
628 Hastie, Yu, Faliti, Grifoni, Ramirez, Haupt, Frazier, Nakao, Rayaprolu, Rawlings, Peters,
629 Krammer, Simon, Sapphire, Smith, Weiskopf, Sette and Crotty 2021, Goldberg et al. 2021,
630 Grifoni, Weiskopf, Ramirez, Mateus, Dan, Moderbacher, Rawlings, Sutherland, Premkumar,
631 Jadi, Marrama, de Silva, Frazier, Carlin, Greenbaum, Peters, Krammer, Smith, Crotty and Sette
632 2020). This fact has recently been underscored by work showing that variants of concern
633 partially escape humoral—but not T-cell-mediated—immune responses in COVID-19
634 convalescent donors and vaccinees (Geers, Shamier, Bogers, den Hartog, Gommers,
635 Nieuwkoop, Schmitz, Rijsbergen, van Osch, Dijkhuizen, Smits, Comvalius, van Mourik, Caniels,
636 van Gils, Sanders, Oude Munnink, Molenkamp, de Jager, Haagmans, de Swart, Koopmans, van
637 Binnendijk, de Vries and GeurtsvanKessel 2021). As the CDC's guidelines on the impact of the
638 vaccination on our lifestyles (travel quarantine and testing, maskless outside and indoors)
639 continues to change and evolve, it remains unclear why immunity conferred by natural
640 infection is not taken into account to support those guidelines, nor is it considered in the
641 progress towards attaining herd-immunity that may enable us to return to the new social
642 normality. In this context, our results are also highly relevant to consider standardizing methods
643 that both serve as a tool to follow up the immune response to the vaccination, but also to provide
644 a correlate of protection.

645

646 **Conflict of Interest**

647 The authors declare that the research was conducted in the absence of any commercial or
648 financial relationships that could be construed as a potential conflict of interest.

649

650 **Authors Contribution**

651 CAS and AME conceptualized the work and supervised the studies. PP supervised the work and
652 performed the serologic, neutralization test and supported the figures design. CSC, TRA, AA
653 execute the serological work. CC and GL selected samples from blood donors. JDB, AKP, CC,

654 GL, PP contribute to the results discussion and analysis. DA, CPC, PP coordinate and supervise
655 the cohort's management and follow up. PP and TRA organized the data for future analysis. TA
656 provided administrative and regulatory support. JDB and AKP designed and supervised the
657 BSL3 work. ETS performed FRNT analysis. CAS wrote the initial draft, with the other authors
658 providing insights and concepts. ETS and AKP conducted the editorial work for the final
659 manuscript.

660

661 **Acknowledgements**

662 Authors want to thank the volunteers that were willing to participate and to contribute to science.
663 To Ilia Toledo, MT, Francheska Rivera, MT and Drs. Ivelisse Martin for their contribution and
664 diligent efforts to provide access to the samples from some presumptive-positive subjects
665 exposed to SARS-CoV-2. Particular acknowledgement is deserved for all administrative and
666 supportive staff at the Medical Sciences Campus, University of Puerto Rico, Laboratorio Clinico
667 Toledo, Laboratorio, Clinico Martin, Banco de Sangre Centro Médico and Banco de Sangre
668 Servicios Mutuos for their availability and commitment during the curfew imposed by the
669 quarantine period. Thanks also to the Latin clinical Trial Center' staff for their dedication
670 providing excellent care to the participants.

671 The Puerto Rico Science, Technology and Research Trust supported research reported in this
672 work under agreement number 2020-00272 to AME and CAS. Also, the University of Puerto Rico
673 contributed with the UPR-COVID-19 Grant to CAS and AME. This work was also supported by
674 1U01CA260541-01 to CAS (NCI/NIAID). This work was also partially funded by Saint Louis
675 University COVID-19 research Seed Funding to awarded to AKP and awarded to JDB.

676

677

678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719

References

- Annen K, Morrison TE, DomBourian MG, McCarthy MK, Huey L, Merkel PA, Andersen G, Schwartz E, Knight V. 2021. Presence and short-term persistence of SARS-CoV-2 neutralizing antibodies in COVID-19 convalescent plasma donors. *Transfusion*. Jan 16. Epub 2021/01/17.
- Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Roupheal N, Creech CB, et al. 2021. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*. Feb 4;384:403-416. Epub 2020/12/31.
- Bradley T, Grundberg E, Selvarangan R, LeMaster C, Fraley E, Banerjee D, Belden B, Louiselle D, Nolte N, Biswell R, et al. 2021. Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine. *New England Journal of Medicine*.
- Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, et al. 2021. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*.371:eabf4063.
- de Thier P, Bacharouche J, Duval JF, Skali-Lami S, Francius G. 2015. Atomic force microscopy analysis of IgG films at hydrophobic surfaces: a promising method to probe IgG orientations and optimize ELISA tests performance. *Biochim Biophys Acta*. Feb;1854:138-145. Epub 2014/12/17.
- Dispinseri S, Secchi M, Pirillo MF, Tolazzi M, Borghi M, Brigatti C, De Angelis ML, Baratella M, Bazzigaluppi E, Venturi G, et al. 2021. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. *Nat Commun*. May 11;12:2670. Epub 2021/05/13.
- Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. 2021. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. *Jama*. May 11;325:1896-1898. Epub 2021/03/20.
- Espino AM, Pantoja P, Sariol CA. 2020. Validation and performance of a quantitative IgG assay for the screening of SARS-CoV-2 antibodies. *bioRxiv*.2020.2006.2011.146332.
- Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti S, Costa C, Nunes-Cabaço H, Mendes AM, Gaspar P, et al. 2020. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. *Eur J Immunol*. Dec;50:2025-2040. Epub 2020/10/22.
- Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, Schmitz KS, Rijsbergen LC, van Osch JAT, Dijkhuizen E, et al. 2021. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. *Science Immunology*.6:eabj1750.
- Goldberg Y, Mandel M, Woodbridge Y, Fluss R, Novikov I, Yaari R, Ziv A, Freedman L, Huppert A. 2021. Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel. *medRxiv*.2021.2004.2020.21255670.
- Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jardi RS, et al. 2020. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell*. May 20. Epub 2020/05/31.

720 Güven E, Duus K, Lydolph MC, Jørgensen CS, Laursen I, Houen G. 2014. Non-specific binding in
721 solid phase immunoassays for autoantibodies correlates with inflammation markers. *J Immunol*
722 *Methods*. Jan 31;403:26-36. Epub 2013/11/30.

723 Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, Mills R, Teng E, Kamruzzaman M,
724 Garcia-Beltran WF, et al. 2020. Persistence and decay of human antibody responses to the
725 receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. *Sci Immunol*. Oct
726 8;5. Epub 2020/10/10.

727 Jeewandara C, Jayathilaka D, Gomes L, Wijewickrama A, Narangoda E, Idampitiya D, Guruge D,
728 Wijayamuni R, Manilgama S, Ogg GS, et al. 2021. SARS-CoV-2 neutralizing antibodies in patients
729 with varying severity of acute COVID-19 illness. *Scientific reports*. Jan 21;11:2062. Epub
730 2021/01/23.

731 Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas
732 JA, Davenport MP. 2021. Neutralizing antibody levels are highly predictive of immune
733 protection from symptomatic SARS-CoV-2 infection. *Nature Medicine*. 2021/05/17.

734 Klingler J, Weiss S, Itri V, Liu X, Oguntuyo KY, Stevens C, Ikegame S, Hung CT, Enyindah-Asonye
735 G, Amanat F, et al. 2020. Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2. *J*
736 *Infect Dis*. Dec 24. Epub 2020/12/29.

737 Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, Bermúdez-
738 González MC, Bielak DA, Carreño JM, Chernet RL, et al. 2021. Antibody Responses in
739 Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med*. Apr
740 8;384:1372-1374. Epub 2021/03/11.

741 Kumar S, Nyodu R, Maurya VK, Saxena SK. 2020. Morphology, Genome Organization,
742 Replication, and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
743 2). In: *Coronavirus Disease 2019 (COVID-19): Epidemiology, Pathogenesis, Diagnosis, and*
744 *Therapeutics*. Singapore: Springer Singapore. p. 23-31.

745 L'Huillier AG, Meyer B, Andrey DO, Arm-Vernez I, Baggio S, Didierlaurent A, Eberhardt CS,
746 Eckerle I, Grasset-Salomon C, Huttner A, et al. 2021. Antibody persistence in the first six months
747 following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study. *Clin*
748 *Microbiol Infect*. Jan 19. Epub 2021/01/23.

749 Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, Ko RLW, Chan KH, Cheng SMS,
750 Perera R, et al. 2021. Neutralizing antibody titres in SARS-CoV-2 infections. *Nat Commun*. Jan
751 4;12:63. Epub 2021/01/06.

752 Mannik M, Kapil S, Merrill CE. 1997. In patients with rheumatoid arthritis IgG binding to
753 denatured collagen type II is in part mediated by IgG-fibronectin complexes. *J Immunol*. Feb
754 1;158:1446-1452. Epub 1997/02/01.

755 Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K,
756 Mahar PL, Edupuganti S, Lalor S, et al. 2008. Human effector and memory CD8+ T cell responses
757 to smallpox and yellow fever vaccines. *Immunity*. May;28:710-722. Epub 2008/05/13.

758 Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, McGuire J, Clearly S,
759 Furrie E, Greig N, et al. 2020. Longitudinal analysis of serology and neutralizing antibody levels
760 in COVID19 convalescents. *J Infect Dis*. Nov 3. Epub 2020/11/04.

761 Nayak K, Gottimukkala K, Kumar S, Reddy ES, Edara VV, Kauffman R, Floyd K, Mantus G,
762 Savargaonkar D, Goel PK, et al. 2021. Characterization of neutralizing versus binding antibodies

763 and memory B cells in COVID-19 recovered individuals from India. *Virology*. Jun;558:13-21.
764 Epub 2021/03/12.

765 Predecki M, Clarke C, Brown J, Cox A, Gleeson S, Guckian M, Randell P, Pria AD, Lightstone L,
766 Xu XN, et al. 2021. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to
767 single-dose BNT162b2 vaccine. *Lancet*. Feb 25. Epub 2021/03/01.

768 Pulendran B, Ahmed R. 2006. Translating innate immunity into immunological memory:
769 implications for vaccine development. *Cell*. Feb 24;124:849-863.

770 Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J,
771 Maurus D, et al. 2020. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell
772 responses. *Nature*. Oct;586:594-599. Epub 2020/10/01.

773 Salazar E, Kuchipudi SV, Christensen PA, Eagar TN, Yi X, Zhao P, Jin Z, Long SW, Olsen RJ, Chen J,
774 et al. 2020. Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro
775 Virus Neutralization in Convalescent Plasma. *bioRxiv*. Jun 9. Epub 2020/06/25.

776 Schmidt F, Weisblum Y, Muecksch F, Hoffmann H-H, Michailidis E, Lorenzi JCC, Mendoza P,
777 Rutkowska M, Bednarski E, Gaebler C, et al. 2020. Measuring SARS-CoV-2 neutralizing antibody
778 activity using pseudotyped and chimeric viruses. *bioRxiv*. 2020.2006.2008.140871.

779 Serrano-Collazo C, Pérez-Guzmán EX, Pantoja P, Hassert MA, Rodríguez IV, Giavedoni L, Hodara
780 V, Parodi L, Cruz L, Arana T, et al. 2020. Effective control of early Zika virus replication by
781 Dengue immunity is associated to the length of time between the 2 infections but not mediated
782 by antibodies. *PLoS Negl Trop Dis*. May;14:e0008285. Epub 2020/05/29.

783 Sette A, Crotty S. 2020. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns.
784 *Nature Reviews Immunology*. 2020/07/07.

785 Steffen TL, Stone ET, Hassert M, Geerling E, Grimberg BT, Espino AM, Pantoja P, Climent C, Hoft
786 DF, George SL, et al. 2020. The receptor binding domain of SARS-CoV-2 spike is the key target of
787 neutralizing antibody in human polyclonal sera. *bioRxiv*. 2020.2008.2021.261727.

788 Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, Quentric P, Fadlallah J, Devilliers H,
789 Ghillani P, et al. 2021. IgA dominates the early neutralizing antibody response to SARS-CoV-2.
790 *Sci Transl Med*. Jan 20;13. Epub 2020/12/09.

791 Tan SS, Saw S, Chew KL, Huak CY, Khoo C, Pajarillaga A, Wang W, Tambyah P, Ong L, Jureen R, et
792 al. 2020. Head-to-head evaluation on diagnostic accuracies of six SARS-CoV-2 serological assays.
793 *Pathology*. Dec;52:770-777. Epub 2020/10/24.

794 Taylor SC, Hurst B, Charlton CL, Bailey A, Kanji JN, McCarthy MK, Morrison TE, Huey L, Annen K,
795 DomBourian MG, et al. 2021. A New SARS CoV-2 Dual Purpose Serology Test: Highly Accurate
796 Infection Tracing and Neutralizing Antibody Response Detection. *Journal of Clinical*
797 *Microbiology*. JCM.02438-02420.

798 Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL,
799 Barnabas SL, Bhorat QE, et al. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine
800 (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,
801 South Africa, and the UK. *Lancet*. Jan 9;397:99-111. Epub 2020/12/12.

802 Wajnberg A, Amanat F, Firpo A, Altman D, Bailey M, Mansour M, McMahan M, Meade P,
803 Mendu DR, Muellers K, et al. 2020. SARS-CoV-2 infection induces robust, neutralizing antibody
804 responses that are stable for at least three months. *medRxiv*. 2020.2007.2014.20151126.

805 Walsh EE, Frenck RW, Jr., Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K,
806 Mulligan MJ, Bailey R, et al. 2020. Safety and Immunogenicity of Two RNA-Based Covid-19
807 Vaccine Candidates. N Engl J Med. Oct 14. Epub 2020/10/15.
808 Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, van den Akker JPC,
809 Molenkamp R, Koopmans MPG, van Gorp ECM, et al. 2020. Phenotype and kinetics of SARS-
810 CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Science
811 Immunology.5:eabd2071.
812
813

814 **FIGURE LEGENDS**
815




Figure 1

816
817
818
819
820 **Figure 1: SARS-CoV-2 specific antibody titers decline over time, while neutralization**
821 **ability is retained.** The threshold for the total antibodies was 0.312. The threshold for IgG
822 titers was 1:100 and for the blocking activity was 30%. Statistical significance was determined
823 by 2way ANOVA multiple comparisons was used to test for increase or decrease among
824 samples. $P < 0.05$ was considered significant. Samples 1 and 2 include the 59 subjects in the
825 initial cohort before vaccination. Sample 3 encompass the 15 subjects from whom a collection
826 of a third sample was completed.
827

828




Figure 2

829

830

831 **Figure 2: Naturally acquired SARS-CoV-2 infection primes an immune response superior**
832 **to a single COVID-19 vaccine dose.**

833 Panel A shows the mean time of sample collection following natural infection (n=25) or after the
834 first vaccine dose (n=20). In panel B and C, results from the total anti-Spike protein and the IgG
835 titer measured by Enzyme-linked immunosorbent assay and expressed as OD or titers
836 respectively are presented. The threshold for the total antibodies was 0.312 and the threshold
837 for IgG titers was 1:100. All participants, except one, with previous exposure to SARS-CoV-2
838 showed detectable antibodies and measurable titers at baseline. Because the threshold 1:100
839 of our titration assay, the IgG titers at baseline in the unexposed subjects—which had no
840 detectable S-specific antibodies—were set arbitrarily to 50. Panel D shows the blocking activity
841 of serum antibodies expressed as percentage of neutralization by using a surrogate viral
842 neutralization test (sVNT). The cutoff for this assay was 30%. As is shown, only one sample in
843 the pre-exposed group contained antibodies below the threshold reported as more than 30% of
844 neutralization. Also, while the distribution of antibodies and titers covers the full Y axis, values
845 in both panel B and C, and in panel D same samples are grouped on the top values area. Two-
846 way ANOVA multiple comparisons or unpaired T test analysis was used to test for increases or
847 decreases among samples. $P < 0.05$ was considered significant. Twenty-five participants
848 (Natural infected) out of the 59 with the first sample collected between 12 and 39 days after the
849 confirmed infection with SARS-CoV-2 were selected for comparison with the 21 unexposed-
850 vaccinated subgroup (Healthy-vaccinated).

851

852




Figure 3

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

Figure 3: Functional neutralization assays are better predictors of the humoral immune response to COVID-19 mRNA-based vaccinations. Samples are described as 1st or 2nd samples after 1st or 2nd vaccine dose (1S-P1st-vd, 1S-P2nd-vd or 2S-P2nd-vd) and the mean time of samples collection is shown. Panels A and B show the total antibody and IgG titers, respectively, after full vaccination with two vaccine doses. Antibody levels and titers significantly decay in both groups in a second sample collected after the second vaccine (average of 60.3 and 100.5 days after the first vaccine dose for the unexposed and pre-exposed groups respectively). Despite the difference in sampling time between the two groups, there were no significant differences in the levels of antibodies or titers between groups in the 2S-P2nd-vd. Panel C shows antibody blocking capabilities measured by a surrogate viral neutralization assay (sVNT). Highly relevant is the finding that the blocking baseline activity of the pre-exposed individuals is significantly higher than the basely blocking activity induced by the first vaccine dose in unexposed individuals. In addition, two vaccine doses were necessary in the unexposed cohort to induce same percentage of neutralization achieved by just the first dose in the pre-exposed group. The magnitude of neutralization remained at similar levels until the last time point evaluated in both groups, confirming that the surrogate neutralization test is more suitable to determine the efficacy of the humoral immune response to the vaccine. The threshold for the total antibodies was 0.312. The threshold for IgG titers was 1:100 and for the blocking activity was 30%. Statistical significance was determined by two-way ANOVA multiple comparisons to test for increase or decrease among samples. $p < 0.05$ was considered significant. The black arrows indicate the moment of vaccine administration related to the timing of sample collection. Healthy-vaccinated (n=21) Pre-exposed vaccinated (n=10).

880 **Supplementary Figure S1: Antibody subclasses isotypes in a longitudinal cohort of 59**
881 **volunteers exposed to SARS-CoV-2.** Panel A shows the total anti-S antibodies in the second
882 set of samples collected an average of 67.8 days after the first set of samples (an average of
883 108 days after PCR-confirmed SARS-CoV-2 infection). A third sample was collected from a
884 subset of the participants (n=12) an average of 99.5 days after the second set of samples (an
885 average of 207 days after infection). Two different patterns in the kinetics of the antibody
886 response were identified: (1) 74.5% of samples showed a decrease in the binding from the time
887 of the first to the second sampling (Panel B) and (2) 25.4% of samples showed increased
888 values relative to the first sampling (Panel C). Panels D-G show the results of antibody binding
889 for the different subclasses tested, with IgG1 being the predominant subclass. Panels H and I
890 show the results for IgM and IgA isotypes. Statistical significance was determined by two-way
891 ANOVA multiple comparisons to test for increase or decrease among samples. $p < 0.05$ was
892 considered significant. Sample 3 encompass the 15 subjects from whom a collection of a third
893 sample was completed. Panels D to I, includes the number of samples, from the initial cohort of
894 59 subjects before vaccination, that were positive for each of the antibody's subtype or
895 subclasses as described in the results section.
896

897 **Supplementary Figure S2: Time elapsed between diagnosis and sample collection was**
898 **not significantly different between groups.** There were no significant differences in the time
899 from diagnostic (Dx) to the first sample collection or between the first and the second samples
900 collection in both groups. Statistical significance was determined by two-way ANOVA multiple
901 comparisons was used. $p < 0.05$ was considered significant. Results are from the 59 subjects in
902 the initial cohort before vaccination. From two subjects in the increased titer and from one in the
903 decreased subgroups we were unable to establish the precise time of diagnostic.
904

905 **Supplementary Figure S3: IgG titers—but not IgM or IgA—correlate with neutralization.**

906 Panel A shows the correlation between the neutralization capacity measured with the surrogate
907 viral neutralization test (sVNT) and the total IgG titers, confirming a moderate agreement. Panel
908 B also shows moderate agreement between the sVNT and Focus Reduction Neutralization Tests
909 (FRNT) using the whole virus. Panels C and D show a fair and a slight agreement between the
910 neutralization activity and the IgM and IgA titers, respectively. All samples (n=131) from the 59
911 subjects in the initial cohort, before vaccination, were included in the analysis for figures in
912 panels A, C and D. A subset of 15 samples with prior known FRNT results, were used for the
913 correlation analysis showed in panel B. Cohen's Kappa agreement follow Landis and Koch scale.
914 The values (κ) were considered as follows: poor agreement, $\kappa < 0.02$; fair agreement, $\kappa = 0.21$ to
915 0.4; moderate agreement, $\kappa = 0.41$ to 0.6; substantial agreement, $\kappa = 0.61$ to 0.8; very good
916 agreement, $\kappa = 0.81$ to 1.0
917

918 **Supplementary Figure S4: Time elapsed between sample collection after vaccination.** The
919 time between the first and second samples after the 1st or the 2nd vaccine dose (1S-P1st-vd, 1S-
920 P2st-vd) were similar in both groups (pre-exposed and unexposed vaccinated subgroups).
921 However, the time of collection of the third sample (2S-P2nd-vd) was significantly longer for the
922 pre-exposed group compared with the unexposed group. Statistical significance was determined
923 by two-way ANOVA multiple comparisons were used. $p < 0.05$ was considered significant.
924 Unexposed and vaccinated group n=21. Pre-exposed and vaccinated group n=10.
925

926 **Supplementary Figure S5: IgG1, IgM and IgA are differentially boosted by the vaccination**
927 **in healthy or pre-exposed vaccinated subgroups.** The boost of the IgG1 in both subgroups
928 agrees with the total antibodies' changes showed in figure 3 after each vaccine dose. First
929 vaccine dose induces a significant increase in the IgM values only in the unexposed healthy
930 subjects. The first vaccine dose significantly boosted the IgA values in both groups. The
931 increase in IgA titers was significantly higher in the pre-exposed vaccinated group compared to
932 the healthy-vaccinated group. The second vaccine boost resulted in an additional significant
933 increase in IgA titers only in the healthy-vaccinated group suggesting an advantage of the
934 second shot in naïve individuals.
935